Released Jun 14, 2023, after the close
10-Q filed Jun 14, 2023, 45 days after period end · 0001654954-23-008014
Q2 2023 · 10-Q
Revenue$4.56M$4.56M −8.1% vs Q2 2022+7.7% vs Q1 2023
Net Income$404.65K$404.65K +68.6% vs Q2 2022−5.1% vs Q1 2023
EPS, diluted—
Gross Profit$1,346,443+10.7%
Operating Income$380,078+35.4%
Operating Cash Flow-$250,107N/M
Free Cash Flowderived-$250,871N/M
Margins · derived
Gross margin29.5%+5.0 pt vs Q2 2022
Operating margin8.3%+2.7 pt vs Q2 2022
Net margin8.9%+4.0 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $4.56M | $4.97M | $5.04M | $5.65M |
| Net Income | $404.65K | $240.03K | $240.27K | $687.56K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR